A comparison of midazolam and dexmedetomidine for the recovery of serotonin syndrome in rats

详细信息    查看全文

• 作者：Takashi Kawano ; Tetsuya Takahashi ; Satomi Kaminaga ; Takao Kadono…
• 关键词：Serotonin syndrome ; Midazolam ; Dexmedetomidine
• 刊名：Journal of Anesthesia
• 出版年：2015
• 出版时间：August 2015
• 年：2015
• 卷：29
• 期：4
• 页码：631-634
• 全文大小：465 KB
• 参考文献：1.Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112鈥?0.CrossRef PubMed
  2.Rastogi R, Swarm RA, Patel TA. Case scenario: opioid association with serotonin syndrome: implications to the practitioners. Anesthesiology. 2011;115:1291鈥?.PubMed
  3.Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005;95:434鈥?1.CrossRef PubMed
  4.Altman CS, Jahangiri MF. Serotonin syndrome in the perioperative period. Anesth Analg. 2010;110:526鈥?.CrossRef PubMed
  5.Akingbola OA, Singh D. Dexmedetomidine to treat lisdexamfetamine overdose and serotonin toxidrome in a 6-year-old girl. Am J Crit Care. 2012;21:456鈥?.CrossRef PubMed
  6.Rushton WF, Charlton NP. Dexmedetomidine in the treatment of serotonin syndrome. Ann Pharmacother. 2014;48:1651鈥?.CrossRef PubMed
  7.Maura G, Gemignani A, Raiteri M. Noradrenaline inhibits central serotonin release through alpha 2-adrenoceptors located on serotonergic nerve terminals. Naunyn Schmiedebergs Arch Pharmacol. 1982;320:272鈥?.CrossRef PubMed
  8.Hopwood SE, Stamford JA. Noradrenergic modulation of serotonin release in rat dorsal and median raph茅 nuclei via 伪1 and 伪2A adrenoceptors. Neuropharmacology. 2001;41:433鈥?2.CrossRef PubMed
  9.Haberzettl R, Bert B, Fink H, Fox MA. Animal models of the serotonin syndrome: a systematic review. Behav Brain Res. 2013;256:328鈥?5.CrossRef PubMed
  10.Sallinen J, Haapalinna A, Viitamaa T, Kobilka BK, Scheinin M. d -amphetamine and l -5-hydroxytryptophan-induced behaviours in mice with genetically altered expression of the alpha2C-adrenergic receptor subtype. Neuroscience. 1998;86:959鈥?5.CrossRef PubMed
  11.Nisijima K, Shioda K, Yoshino T, Takano K, Kato S. Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome. Neurochem Int. 2003;43:155鈥?4.CrossRef PubMed
  12.Carollo DS, Nossaman BD, Ramadhyani U. Dexmedetomidine: a review of clinical applications. Curr Opin Anaesthesiol. 2008;21:457鈥?1.CrossRef PubMed
  
• 作者单位：Takashi Kawano (1) (2)
  Tetsuya Takahashi (1)
  Satomi Kaminaga (2)
  Takao Kadono (2)
  Daiki Yamanaka (1)
  Hideki Iwata (1)
  Satoru Eguchi (3)
  Masataka Yokoyama (1) (2)
  
  1. Department of Anesthesiology and Intensive Care Medicine, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan
  2. Center for Innovative and Translational Medicine, Interdisciplinary Pain Research Team, Kochi Medical School, Nankoku, Kochi, Japan
  3. Department of Dental Anesthesiology, Tokushima University School of Dentistry, Tokushima, Japan
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Anesthesiology
  
• 出版者：Springer Japan
• ISSN：1438-8359

文摘

Serotonin syndrome is a drug-related toxicity caused by excess serotonin within the central nervous system. We recently encountered a case of serotonin syndrome that developed in the early postoperative period that was successfully treated with intravenous dexmedetomidine. Although the prescriptive literature has commonly recommended sedation with benzodiazepines for controlling agitation in serotonin syndrome, the effectiveness of dexmedetomidine has also been reported in several clinical conditions. In the present study, we conducted a reverse translational experiment to compare the efficacy of dexmedetomidine and midazolam, at equi-sedative doses, on serotonergic toxicity-like responses in rats. Animals were subcutaneously injected with 0.75 mg/kg 8-OH-DPAT, a full 5-HT_1A agonist. 8-OH-DPAT-treated rats showed serotonin syndrome-like behaviors (low body posture, forepaw treading), hyperlocomotion, and decreased body temperature, which were completely inhibited by pretreatment with WAY 100635, a selective 5-HT_1A antagonist (n = 8). Intramuscular injection of midazolam (1.0 mg/kg) or dexmedetomidine (0.01 mg/kg), which comparably induced observable signs of sedation, was tested in the present study. Concomitant treatment with midazolam significantly attenuated the hyperlocomotion, but failed to affect traditional serotonin syndrome behaviors and body temperature in 8-OH-DPAT-treated rats (n = 8). On the other hand, concomitant treatment with dexmedetomidine significantly attenuated all of these parameters (n = 8). The present case and related reverse translational experiment demonstrate that dexmedetomidine may be more beneficial for the treatment of serotonin syndrome compared to the current recommended treatment with benzodiazepines. Keywords Serotonin syndrome Midazolam Dexmedetomidine